A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.

IF 3.1 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2026-07-01 Epub Date: 2026-07-16 DOI:10.1080/14796694.2026.2692029

Filippo de Marinis, Tae Min Kim, Laura Bonanno, Susanna Cheng, Sang-We Kim, Marcello Tiseo, Quincy Chu, Claudia Proto, Adrian Sacher, Yung-Hung Luo, Silvia Novello, Desiree Hao, Christina Baik, Lyudmila Bazhenova, Jong Seok Lee, Byoung Chul Cho, Jacques Cadranel, Tuan Bao Diep, Giulio Metro, Prasad Narayanan, Yasuto Yoneshima, Javier de Castro Carpeño, Clarissa Baldotto, James Chih-Hsin Yang, Lecia V Sequist, Benjamin Levy, Ryan Hartmaier, Ike Igwegbe, Lynne Poole, Wanning Xu, Myung-Ju Ahn

引用次数: 0

查看原文本刊更多论文

萨凡纳研究的简单语言总结：savolitinib加奥西替尼治疗egfr突变的晚期非小细胞肺癌，MET过表达和/或扩增，肿瘤在奥西替尼上生长或扩散。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.